Beyond their glucose-lowering effects, DPP-4 inhibitors have been implicated in processes relevant to both atherosclerosis and CAVS, particularly in individuals with type 2 diabetes mellitus, a population prone to overlapping vascular and valvular pathologies [82]. The gene discussed is DPP4; the disease is diabetes mellitus.